Press releases

9 Dec 2022

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

7 Dec 2022

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

1 Dec 2022

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

22 Nov 2022

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

14 Nov 2022

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

10 Nov 2022

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Press releases

Press releases

Search Press releases

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Choose a Country

UCB and Ailux Biologics Join Forces to Transform Biologics Research

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in...

RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

UCB Submits Response to FDA Complete Response Letter for Bimekizumab

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Choose a Country